Zevra Therapeutics Inc. Total Liabilities
Zevra Therapeutics Inc. total liabilities. Based on the latest financial reports, Zevra Therapeutics Inc. (ZVRA) has total liabilities worth $136.95 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Zevra Therapeutics Inc.'s assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Zevra Therapeutics Inc. (2012–2024)
Total liabilities of Zevra Therapeutics Inc. from 2012 to 2024. This chart illustrates how Zevra Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore ZVRA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Zevra Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Zevra Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wam Global Ltd
AU:WGB
|
Australia | AU$18.95 Million |
|
Suzhou Xingye Material Tech
SHG:603928
|
China | CN¥405.49 Million |
|
Farmacias Benavides S.A.B. de C.V.
MX:BEVIDESB
|
Mexico | MX$5.49 Billion |
|
Zhejiang Zoenn Design Co Ltd
SHE:300901
|
China | CN¥437.90 Million |
|
Veradigm Inc.
NASDAQ:MDRX
|
USA | $513.64 Million |
|
Puyang Refractories Group Co Ltd
SHE:002225
|
China | CN¥4.98 Billion |
|
4D Molecular Therapeutics Inc
NASDAQ:FDMT
|
USA | $61.05 Million |
|
Marssenger Kitchenware Co. Ltd.
SHE:300894
|
China | CN¥990.78 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Zevra Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Zevra Therapeutics Inc. assets under control.
Liquidity & Leverage Metrics
Zevra Therapeutics Inc. Total Liabilities Ratios Explained
Zevra Therapeutics Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zevra Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zevra Therapeutics Inc. (2012–2024)
The table below shows the annual total liabilities of Zevra Therapeutics Inc. from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $138.46 Million | +25.35% |
| 2023-12-31 | $110.46 Million | +174.65% |
| 2022-12-31 | $40.22 Million | +590.71% |
| 2021-12-31 | $5.82 Million | -92.50% |
| 2020-12-31 | $77.62 Million | -8.64% |
| 2019-12-31 | $84.96 Million | -8.95% |
| 2018-12-31 | $93.31 Million | -15.15% |
| 2017-12-31 | $109.97 Million | +6.17% |
| 2016-12-31 | $103.58 Million | +57.32% |
| 2015-12-31 | $65.84 Million | +73.20% |
| 2014-12-31 | $38.02 Million | +42.40% |
| 2013-12-31 | $26.70 Million | +650.04% |
| 2012-12-31 | $3.56 Million | -- |
About Zevra Therapeutics Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under P… Read more